Windlas Biotech Ltd
WINDLAS NSE
Windlas Biotech Ltd
HealthcareNSE: WINDLAS BSE: 543329 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹2,075 Cr
Volatility
Moderate
P/E Ratio
31.28
EBITDA
₹123 Cr
Return on Equity
11.44%
Debt to Equity
0.06
Book Value
₹281.35
EPS
₹28.52
52W High
₹1,035.9
52W Low
₹697.4
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Windlas Biotech Ltd insights
47 extracted metrics + investor summaries across FY16–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
4- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 19.8%
- Promoter holding has increased by 1.41% over last quarter.
- Company's working capital requirements have reduced from 21.4 days to 14.4 days
Weaknesses
1- Company has a low return on equity of 12.8% over last 3 years.
Growth Rate
Revenue Growth
18.51% ↗
Net Income Growth
9.02% ↗
Cash Flow Change
53.88% ↗
ROE
-5.14% ↘
ROCE
-4.98% ↘
EBITDA Margin (Avg.)
-7.77% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 145 | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 | 248 |
| Expenses | 128 | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 | 221 |
| Operating Profit | 17 | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 | 27 |
| OPM % | 12% | 12% | 13% | 13% | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% | 11% |
| Other Income | 3 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 3 | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 | 7 |
| PBT | 16 | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 | 23 |
| Tax % | 26% | 23% | 24% | 25% | 26% | 23% | 24% | 22% | 24% | 25% | 25% | 21% | 23% |
| Net Profit | 12 | 14 | 15 | 17 | 13 | 16 | 15 | 16 | 18 | 18 | 15 | 16 | 18 |
| EPS in Rs | 5.8 | 6.75 | 7.26 | 8.15 | 6.45 | 7.49 | 7.29 | 7.77 | 8.43 | 8.45 | 7.09 | 7.59 | 8.55 |
Profit & Loss
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 274 | 315 | 320 | 288 | 329 | 428 | 466 | 513 | 631 | 760 | 904 | 942 |
| Expenses | 253 | 290 | 284 | 244 | 288 | 373 | 413 | 453 | 553 | 666 | 799 | 837 |
| Operating Profit | 20 | 25 | 36 | 44 | 41 | 55 | 53 | 60 | 78 | 94 | 105 | 105 |
| OPM % | 7% | 8% | 11% | 15% | 12% | 13% | 11% | 12% | 12% | 12% | 12% | 11% |
| Other Income | 1 | 4 | 5 | 2 | 1 | -29 | 7 | 10 | 13 | 18 | 18 | 18 |
| Interest | 7 | 5 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 4 | 5 | 5 |
| Depreciation | 9 | 9 | 11 | 8 | 9 | 13 | 12 | 12 | 13 | 28 | 31 | 31 |
| PBT | 6 | 14 | 25 | 35 | 31 | 11 | 46 | 57 | 77 | 79 | 87 | 87 |
| Tax % | 20% | 35% | 33% | 36% | 27% | 55% | 16% | 25% | 25% | 24% | 24% | — |
| Net Profit | 5 | 9 | 17 | 22 | 22 | 5 | 39 | 43 | 58 | 61 | 66 | 66 |
| EPS in Rs | 8.14 | 16.41 | 30.24 | 35.05 | 35.03 | 7.81 | 17.69 | 20.05 | 27.95 | 28.94 | 31.48 | 31.68 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 20% | 20% | 20% | 20% | 20% | — |
Balance Sheet
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 11 | 10 | 10 | 10 | 11 |
| Reserves | 132 | 141 | 158 | 188 | 210 | 193 | 384 | 392 | 440 | 495 | 570 |
| Borrowings | 53 | 62 | 43 | 30 | 27 | 32 | 7 | 5 | 4 | 33 | 35 |
| Other Liabilities | 90 | 94 | 93 | 73 | 100 | 65 | 89 | 121 | 172 | 222 | 291 |
| Total Liabilities | 281 | 304 | 299 | 297 | 344 | 296 | 491 | 529 | 626 | 760 | 907 |
| Fixed Assets | 56 | 56 | 58 | 62 | 68 | 96 | 91 | 109 | 179 | 223 | 213 |
| CWIP | 9 | 15 | 11 | 5 | 0 | 0 | 8 | 15 | 6 | 5 | 60 |
| Investments | 95 | 121 | 123 | 121 | 121 | 23 | 65 | 107 | 173 | 223 | 268 |
| Other Assets | 121 | 111 | 107 | 110 | 154 | 177 | 327 | 298 | 268 | 308 | 366 |
| Total Assets | 281 | 304 | 299 | 297 | 344 | 296 | 491 | 529 | 626 | 760 | 907 |
Cash Flow
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 47 | 7 | 39 | 22 | 21 | 11 | 9 | 61 | 109 | 68 | 105 |
| Investing | -62 | -39 | -11 | -7 | -9 | -20 | -154 | -14 | -92 | -74 | -92 |
| Financing | 38 | 5 | -25 | -8 | -6 | 1 | 130 | -44 | -15 | 1 | -13 |
| Net Cash Flow | 24 | -27 | 4 | 7 | 5 | -8 | -15 | 3 | 2 | -5 | 0 |
| Free Cash Flow | 35 | -8 | 28 | 12 | 11 | 6 | -6 | -9 | 71 | 16 | 37 |
| CFO/OP | 249 | 34 | 122 | 80 | 84 | 33 | 34 | 117 | 163 | 95 | 115 |
Ratios
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 70 | 68 | 79 | 72 | 68 | 87 | 83 | 79 | 80 | 92 |
| Inventory Days | 49 | 62 | 44 | 38 | 85 | 55 | 71 | 84 | 57 | 63 | 40 |
| Days Payable | 137 | 120 | 124 | 117 | 143 | 53 | 76 | 98 | 121 | 138 | 156 |
| Cash Conversion Cycle | -14 | 13 | -12 | 0 | 13 | 70 | 82 | 69 | 15 | 6 | -24 |
| Working Capital Days | -46 | -37 | 2 | -12 | 3 | 40 | 86 | 72 | 32 | 18 | 14 |
| ROCE % | — | 10% | 13% | 18% | 14% | 19% | 15% | 14% | 18% | 17% | 16% |
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Company confirmed it is not a Large Corporate for FY 2026-27 under SEBI circular. 30 Apr - Company confirmed it is not a Large Corporate for FY 2026-27 under SEBI circular.
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Apr - Submission of newspaper publications regarding dispatch of Letter of Offer of Buyback to the shareholders of the Company 29 Apr - Submission of newspaper publications regarding dispatch of Letter of Offer of Buyback to the shareholders of the Company
3
Submission Of Letter Of Offer
27 Apr - Windlas Biotech opens ₹47 crore buyback for 4.70 lakh shares at ₹1,000 each; window April 30–May 7, 2026. 27 Apr - Windlas Biotech opens ₹47 crore buyback for 4.70 lakh shares at ₹1,000 each; window April 30–May 7, 2026.
4
Announcement under Regulation 30 (LODR)-Change in Directorate
5 May - Dr. Tarashree Singhal appointed Independent Woman Director from May 5, 2026; Srinivasan Venkataraman steps down. 5 May - Dr. Tarashree Singhal appointed Independent Woman Director from May 5, 2026; Srinivasan Venkataraman steps down.
5
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Company confirmed it is not a Large Corporate for FY 2026-27 under SEBI circular. 30 Apr - Company confirmed it is not a Large Corporate for FY 2026-27 under SEBI circular.
Frequently Asked Questions about Windlas Biotech Ltd
What does Windlas Biotech Ltd do?
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product ...
Where is Windlas Biotech Ltd (WINDLAS) listed?
Windlas Biotech Ltd is listed on the Indian stock exchanges. It is listed on NSE: WINDLAS and BSE: 543329. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Windlas Biotech Ltd belong to?
Windlas Biotech Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Windlas Biotech Ltd?
Windlas Biotech Ltd has a market capitalisation of approximately ₹2075.08 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Windlas Biotech Ltd?
The Price-to-Earnings (PE) ratio of Windlas Biotech Ltd is 31.28. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Windlas Biotech Ltd?
Over the past 52 weeks, Windlas Biotech Ltd has traded between a low of ₹697.4 and a high of ₹1,035.9. This range helps investors understand the stock's price volatility and recent trading levels.
Does Windlas Biotech Ltd pay dividends?
Yes, Windlas Biotech Ltd has a dividend yield of 0.64%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Windlas Biotech Ltd?
Windlas Biotech Ltd has a Return on Equity (ROE) of 11.44%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Windlas Biotech Ltd on Tapetide?
On Tapetide, you can view Windlas Biotech Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.[1]